United States - English - NLM (National Library of Medicine)

hospira, inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. lymphomas hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin has also been shown to be useful in the management of: malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to i

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - bleomycin sulfate 10 mg - eq. bleomycin 15000 iu - powder for solution for injection/infusion - 15000 iu - bleomycin sulfate 10 mg - bleomycin

United States - English - NLM (National Library of Medicine)

cipla usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - bleomycin sulfate -

United States - English - NLM (National Library of Medicine)

northstar rx llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bleomycin sulfate 15000 [iu];   - powder for injection - 15000 iu - active: bleomycin sulfate 15000 [iu]   excipient: water for injection - dbl™ bleomycin sulfate for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents; squamous cell carcinoma: head and neck including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingiva, epiglottis, skin, larynx, penis, cervix, and vulva. the response to bleomycin sulfate is poorer in patients with head and neck cancer previously irradiated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: - bleomycin is used for palliation and/or treatment adjuvant to surgery and radiation therapy and in the management of the following neoplasms: squamous cell carcinoma of the skin, head and neck, and oesophagus is the primary indication for bleomycin. tumour response has been obained in a number of patients with squamous cell carcinoma of the penis, larynx and uterine cervix. infrequent response has been shown in squamous cell carcinoma of the bronchus. treatment of choriocarcinoma and embryonal cell carcinoma of the testis is also indicated. bleomycin has been effectively used in advanced hodgkin's disease and in some cases of other lymphomas such as non-hodgkin's, and also in cases of mycosis fungoides.

Canada - English - Health Canada

sandoz canada incorporated - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - bleomycin sulfate 15 mg - powder for solution for injection - 15000 iu - bleomycin sulfate 15 mg - bleomycin

Canada - English - Health Canada

fresenius kabi canada ltd - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents